Authors: HoJin Shin Joo Seop Chung MooKon Song SeonKyeong Kim Sangmin Choe GoonJae Cho
Publish Date: 2012/01/04
Volume: 69, Issue: 5, Pages: 1165-1172
Abstract
The aim of this study was to evaluate the efficacy and toxicity of reduceddose RD RCHOP rituximab combined with cyclophosphamide doxorubicin vincristine and prednisolone chemotherapy for elderly patients with diffuse large Bcell lymphoma DLBCLThis study comprised 85 patients aged ≥60 years who were diagnosed with DLBCL patients were enrolled at a single center between June 2004 and December 2009 Patients received either 6 or 8 cycles of RDRCHOP spaced 3 weeks apart at the physician’s discretion The RDRCHOP regimen consisted of 375 mg/m2 rituximab 600 mg/m2 cyclophosphamide 30 mg/m2 doxorubicin and 1mg vincristine on day 1 of each cycle and 40mg prednisone on days 1–5 The patients received granulocyte colonystimulating factor if they experienced grade 4 neutropenia or febrile neutropenia during any cycleThe average relative dose intensity was 973 for doxorubicin and 974 for cyclophosphamide The complete remission CR and overall response rate were 671 and 895 respectively The 3year eventfree survival and overall survival rates were 719 ± 51 and 833 ± 51 By using multivariate analyses we determined that Creactive protein levels greater than 131 mg/dl and the absence of CR were poor prognostic factors Grade 3 or 4 neutropenia occurred in 353 of patients and febrile neutropenia occurred in only 3 35 patients
Keywords: